15 jun: IMF OKs Terms for Funds Pledged to Boost Resources
16 jun: Monsanto to Invest $355 Million in Argentina Corn-Seed Plant
15-06-2012 23:53:00

Merck Loses Nasonex Patent Suit; Says Likely to Appeal

Relateret indhold

By Ben Fox Rubin

Drug maker Merck & Co. (MRK) said a U.S. district court ruled against it in a patent-infringement suit involving Apotex Inc.

In 2009, Merck filed the suit in New Jersey in an effort to block Apotex, a Canadian generic drug manufacturer, from selling a generic copy of Merck's blockbuster allergy drug Nasonex before U.S. patent protection expires.

Apotex had challenged the validity of the U.S. patent covering Nasonex. Merck said its patent for Nasonex is due to expire in 2018.

Bruce N. Kuhlik, Merck's general counsel, said his company was pleased the court ruled that its patent on Nasonex is valid, but was disappointed the court said the patent wasn't infringed by Apotex's product.

"Today's decision reflects just one step in the lengthy patent litigation process, and we plan to review all of our options, including a likely appeal of the decision," Mr. Kuhlik said.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

In April, Merck said its first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed Friday at $38.94 and were down 14 cents after hours. The stock is up 3.3% year-to-date.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 15, 2012 17:53 ET (21:53 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

FLSmidth: Kobberprisen gjorde comeback i februar

27-02-2015 15:57:04
Kobberprisen har gjort et lille comeback i februar, hvor det for FLSmidth så vigtige metal har klaret sig bedst blandt industrimetallerne noteret på London Meta..

Maersk Drilling/CEO: Raterne er faldet markant

27-02-2015 12:39:21
De fede år er ovre, og nu står den på smalhals i store dele af oliebranchen, både for producenterne og underleverandørerne.Det rammer Maersk Drilling og branche..

Aktier/åbning: Investorerne vender tomlen op for NKT

27-02-2015 09:32:27
Regnskabet fra det danske industriselskab NKT giver anledning til at sende aktien yderligere til vejrs. Sådan lyder dommen fra investorerne fredag morgen, hvor ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
ØK: Kommer ud af 2014 med stort plus i forhold til 2013
2
Aktier/tendens: NKT til eksamen efter kursridt
3
Novos vægttabsmiddel nu også godkendt i Canada
4
Danmark/Analytikere: Økonomer splittet omkring BNP-tal - NY
5
Vind: Vattenfall gør vindmøllepark 2,2 milliarder billigere

Relaterede aktiekurser

Merck & Co., Inc 58,64 -0,5% Fald i aktiekurs
Merck AND CO Inc 52,58 0,8% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. februar 2015 17:49:33
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150225.2 - EUROWEB5 - 2015-02-27 17:49:33 - 2015-02-27 17:49:33 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x